Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT00022698

Public ClinicalTrials.gov record NCT00022698. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.

Study identification

NCT ID
NCT00022698
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
67 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2001
Primary completion
Nov 30, 2004
Completion
Nov 30, 2004
Last update posted
Apr 14, 2016

2001 – 2004

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
15
Facility City State ZIP Site status
University of Alabama at Birmingham Comprehensive Cancer Center Birmingham Alabama 35294-3300
Loma Linda University Cancer Institute at Loma Linda University Medical Center Loma Linda California 92354
Eastern Connecticut Hematology and Oncology Associates Norwich Connecticut 06360
Lombardi Cancer Center at Georgetown University Medical Center Washington D.C. District of Columbia 20007
George Washington University Medical Center Washington D.C. District of Columbia 20037
University of Florida Health Science Center - Jacksonville Jacksonville Florida 32209
Markey Cancer Center at University of Kentucky Chandler Medical Center Lexington Kentucky 40536-0084
St. Louis University Hospital Cancer Center St Louis Missouri 63110-0250
HemOnCare, P.C. Brooklyn New York 11235
Lincoln Medical and Mental Health Center The Bronx New York 10451
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia Philadelphia Pennsylvania 19107-5541
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Charleston Hematology-Oncology, P.A. Charleston South Carolina 29403
Cancer Center at the University of Virginia Charlottesville Virginia 22908
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus Seattle Washington 98104
Rockwood Clinic P.S. Spokane Washington 99202
West Virginia University Hospitals Morgantown West Virginia 26506-9300

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00022698, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 14, 2016 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00022698 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →